Updated

Startup Efferon, selected for the Battlefield 200 accelerator program, has developed blood-purification technology aimed at reducing the devastating toll of pediatric sepsis. The technology represents an innovative approach to treating one of the leading causes of mortality in children, addressing a critical gap in pediatric critical care.